UPDATE 1-Perry acquires 9.89 percent stake in Mylan Labs
450382
Investment firm Perry Corp. on Monday said it holds a 9.89 percent stake in Mylan Laboratories Inc. (MYL.N: Quote, Profile, Research) , exceeding the holdings of financier Carl
720072
Dolan Media Co., a provider of professional  services to the legal, financial and real estate sectors, on  Wednesday registered its initial public offering of 10.5  million shares at an estimated price of $13.50 to $15.50 per  share.
580086
WASHINGTON (CBS.MW) -- Mylan Laboratories (MYL) , responding to the latest in a series of letters from investor Carl Icahn, reasserted its position that acquiring King Pharmaceuticals (KG) is in the long-term interest of the generic drugmaker and its
195777
Investor Carl C. Icahn on Monday said he bought more shares of Mylan Laboratories (MYL:NYSE - news - research), while unleashing more criticism of the company&#39;s effort to acquire King Pharmaceuticals.
303470
(InfoWorld) - A U.S. private investment company appears to be trying to grab a larger stake of Japan's NEC Electronics. Perry Capital has offered to increase its stake in the company, which is the chip-making subsidiary of NEC, from its current stake of around 4.5 percent to 25 percent, according to a report in Wednesday morning's Nihon Keizai Shimbun business daily. NEC confirmed that it was approached by Perry Capital but would not disclose details. "NEC received a letter from an American private investment firm, Perry Capital, on July 11, 2007; however, NEC cannot comment on the contents of individual communications with investors," it said. The news comes a day after NEC said its semiconductor subsidiary is a candidate for delisting from the Tokyo Stock Exchange because too many of its shares are held by a small number of shareholders. The exchange regulations say a company cannot remain listed if more than 75 percent of its shares are held by its 10 largest shareholders. NEC Electronics has until March 2008 to adjust the shareholding, although new rules slated for later this year would change the criteria for delisting. If they come into force as expected, NEC Electronics could continue to trade with no change in its shareholder status. NEC Electronics stock ended the day up 16 percent, at a year-high of Â¥3,670.
550625
Financier Carl Icahn on Friday  offered to buy the shares of generic drugmaker Mylan  Laboratories MYL.N that he does not already own for $4.9  billion, or $20 a share, according to a government filing.
592758
The drug maker Mylan Laboratories Inc. appeared to back away yesterday from a contentious $4 billion takeover bid for rival King Pharmaceuticals Inc. King shares fell more than 6 percent on the news.
609796
Despite concerns raised by an investor, Mylan Laboratories Inc. reaffirmed that its proposed acquisition of generic drug maker King Pharmaceuticals Inc.
402032
Mylan Laboratories Inc. (MYL.N: Quote, Profile, Research) , a maker of generic drugs, and King Pharmaceutical (KG.N: Quote, Profile, Research) on Wednesday reaffirmed their commitment
84238
Mylan Laboratories Inc. MYL.N on  Friday said its board of directors remains committed to the  purchase of King Pharmaceuticals Inc. KG.N, despite news that  billionaire investor Carl Icahn won regulatory approval to buy  up to 11.9 percent of Mylan's shares.
150469
U.S. investment fund Perry Capital has offered to buy an additional 25 percent stake in ailing Japanese chip maker NEC Electronics Corp.  for 154 billion yen ($1.27 billion), a source close to the matter said on Wednesday.
618563
Mazu Networks, the Cambridge, Massachusetts, network intrusion prevention system (IPS) technology company, has secured another round of venture capital funding, including a stake from security software giant Symantec.
587421
Investors kept their eye on makers of generic pharmaceuticals Monday with news that Mylan Laboratories Inc. received Food and Drug Administration approval to market a generic version of a Novartis AG hypertension
561858
-- Mylan Laboratories  Inc.MYL.N on Wednesday said it is unlikely to complete its  $3.37 billion acquisition of King Pharmaceuticals Inc.KG.N at  the current price because of King's need to restate earnings.
292602
Drugmaker Mylan Laboratories Inc.  posted a quarterly loss on Thursday on charges related to an acquisition, but reported adjusted profit that beat its previous forecast helped by sales of generic drugs for pain and bladder control.
406523
UBS Global Asset Management told Mylan Laboratories Inc. that Mylan&#39;s proposed acquisition of King Pharmaceuticals Inc. is dilutive to Mylan shareholders and not in the best interests of the investment firm&#39;s
45146
Texas power company TXU Corp.   has agreed to be acquired by private equity firms Kohlberg  Kravis Roberts & Co.  and Texas Pacific Group   for about $32 billion in the largest leverage buyout in  history, Bloomberg News reported on Monday.